Koizumi S, Fujimoto T, Oka T, Watanabe S, Kikuta A, Tsuchiya T, Matsushita T, Asami K, Yanase T, Mimaya J, Ohta S, Miyake M, Nishikawa K, Furuyama T, Yamamura Y, Takaue Y, Ninomiya T, Shimokawa T, Iwai A, Ishida Y, Ariyoshi N, Kimura K, Kawakami K, Gushiken T, Sekine I
Department of Pediatrics, Kanazawa University School of Medicine, Japan.
Pediatr Hematol Oncol. 1997 Jan-Feb;14(1):17-28. doi: 10.3109/08880019709030881.
Since 1981, the Children's Cancer and Leukemia Study Group (CCLSG) has developed a series of protocols for treatment of acute lymphoblastic leukemia (ALL) in childhood. In the first randomized controlled study of the 811 protocol (1981-1983) a comparison of conventional daily 6-mercaptopurine and methotrexate with a pulsed regimen of the two drugs was performed. The superiority of the pulsed regimen was shown. In the next 841 protocol (1984-1987) a comparison of two drugs and three drugs during induction therapy was conducted. The three-drug regimen resulted in a significantly higher event-free survival (EFS) rate. In the 874 protocol (1987-1990) two regimens with or without cranial irradiation were randomly compared, and there was no significant difference between the two regimens for the standard-risk group. To further improve the EFS rate a risk group-directed protocol 911 was conducted starting in January 1991. Life-table analysis of serial CCLSG protocols revealed that the outcome of overall ALL has gradually improved with an increase of the EFS rate; 41.4% +/- 3.6% at 14 years for the 811 protocol, 51.3% +/- 3.5% at 11 years for the 841 protocol, 56.7% +/- 3.1% at 8 years for the 874 protocol, and 78.2% +/- 3.1% at 4 years for the more recent 911 protocol.
